Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report

At the end of the 8 week benralizumab dosing interval, severe broncho-obstruction developed, and the next injection of benralizumab was administered during ICU admission without detrimental symptoms. Authors hope this case report will help guide doctors in future decision making.

Source:

European Journal of Hospital Pharmacy